Share This Page
Suppliers and packagers for EURAX
✉ Email this page to a colleague
EURAX
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Journey | EURAX | crotamiton | CREAM;TOPICAL | 006927 | NDA | Journey Medical Corporation | 69489-311-60 | 1 TUBE in 1 CARTON (69489-311-60) / 60 g in 1 TUBE | 2026-03-16 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug EURAX
What companies manufacture or supply EURAX (Alverine citrate)?
EURAX is a branded formulation containing alverine citrate, a drug used primarily for gastrointestinal disorders, especially irritable bowel syndrome. Manufacturing and supply of EURAX are controlled by specific pharmaceutical companies, which often hold patent rights or licensing agreements.
Who are the primary suppliers or manufacturers of EURAX?
EURAX is marketed predominantly by Boehringer Ingelheim. The company holds extensive rights over the drug's formulation and distribution.
Manufacturing and Supply Overview
| Company | Role | Key Details |
|---|---|---|
| Boehringer Ingelheim | Primary manufacturer, marketer | Produces EURAX in various markets worldwide. This includes manufacturing active pharmaceutical ingredient (API) and finished dosage forms. |
| Contract manufacturing organizations (CMOs) | Contract producers | Several CMOs may produce active ingredients or finished products under licensing agreements with Boehringer Ingelheim. The specific names are proprietary and vary by region. |
Distribution Partners
- Boehringer Ingelheim manages distribution through regional subsidiaries.
- Licensing agreements with third-party wholesalers and pharmacies globally, especially in Europe and Asia.
Is EURAX available through global generic manufacturers?
No. EURAX's formulation is patent-protected under Boehringer Ingelheim patents, limiting generic competition. The expiration of key patents is a potential future factor for generic manufacturers to enter the market.
Are there alternative formulations or similar drugs?
Yes. Several other brands contain alverine citrate, including:
- Aventis (e.g., Spasmonal)
- Sandoz (generic versions of alverine citrate)
- Other regional brands or generics depending on patent status.
However, these are not labeled as EURAX; they are marketed under different brand names or as generics.
Key considerations for procurement and supply chain
- Patent status: Patents protect EURAX, restricting the entry of generics.
- Regional licensing: Distribution rights are region-specific.
- Supply chain stability: Dependence on Boehringer Ingelheim or licensed CMO facilities affects supply security.
- Regulatory approvals: Manufacturing sites must comply with regional Good Manufacturing Practices (GMP).
Summary
- Controlled by: Boehringer Ingelheim
- Main manufacturing: Boehringer Ingelheim facilities and licensed CMOs
- Distribution: Managed regionally via subsidiaries and licensing agreements
- Generics and alternatives: Limited until patent expiry or license expiration
Key Takeaways
- Boehringer Ingelheim remains the sole producer of EURAX.
- Patent protections restrict generic entry currently.
- Supply chain stability depends on Boehringer Ingelheim's manufacturing and licensing practices.
- Alternatives with alverine citrate are available under different brands but not as EURAX.
- Future generic availability depends on patent expiration and licensing developments.
FAQs
1. Which companies currently hold licenses to produce EURAX?
Boehringer Ingelheim holds the primary licensing rights. Specific licensing agreements with third-party manufacturers are not publicly disclosed but are managed regionally.
2. Can generic manufacturers produce alverine citrate drugs similar to EURAX?
Generic companies can produce alverine citrate formulations once patents expire and licensing agreements allow, but currently, patent protection limits this.
3. How can I verify the manufacturing source of EURAX in a specific region?
Check the packaging for manufacturing site information, or consult regulatory filings with agencies like the EMA or FDA. Boehringer Ingelheim’s regional offices can also provide supply chain details.
4. Are there any announced patent expirations affecting EURAX?
No publicly available patent expirations have been announced yet; patent status should be regularly monitored for future market opportunities.
5. What are the risks associated with supply dependency on a single manufacturer?
Risks include supply disruptions, regulatory challenges, or manufacturing issues at Boehringer Ingelheim or its licensed CMOs, impacting drug availability.
References
[1] European Medicines Agency. (2022). Summary of product characteristics: EURAX. Retrieved from https://www.ema.europa.eu/en/documents/product-information/eurax-epar-product-information_en.pdf
[2] Boehringer Ingelheim. (2023). Product portfolio overview. Retrieved from https://www.boehringer-ingelheim.com
[3] U.S. Food and Drug Administration. (2020). Approved Drug Products With Therapeutic Equivalence Evaluations.
More… ↓
